Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Another Dustin mistake was over hiring of the aesthetic sales team! There were reps in almost every region who did not have enough active accounts to make their quota so these reps are leaving and these territories should never have been created! These territories are being divided up between existing reps.
70% of the Therapeutic sales team has been hired which would indicate potential CD sales starting April 1st. CD/Therapeutic orders are being taken now and which will create a nice bubble of shipment dollars when the green light is turned on.
Mark Foley is a total train wreck! This guy has no clue how to run a company!!!
Per practice websites and physician locator:
To add a page to a practice website for Daxi, the practice will have to pay their website designer a $1000 to $2000. Most practices will wait and make sure they are committed to providing the product before updating the website. So there is typically a lag for new products/procedures.
The Daxi Physician Finder was developed by the internal IT department who was fired. The requirement to be on the Physician Finder was that the practice ordered a minimum of 50 vials per month or something like this. Was a ridicules requirement which did not allow many of the smaller providers to be listed. This was a Dustin rule which was eliminated with Dustin. There were a lot of bad decisions made which Foley claims he did not know about! BS!!!
The shorts have started to cover.
Has been 11 months since the number is this low. 12,647,853 or 17.32% Still high and I suspect the short number will continue to decline.
01/31/2024 12,647,853 1,506,005 8.398281
01/12/2024 14,805,080 1,877,752 7.88447
12/29/2023 14,390,139 1,062,681 13.541353
12/15/2023 12,395,236 1,379,800 8.983357
11/30/2023 13,068,468 1,384,228 9.440979
11/15/2023 14,633,195 2,380,624 6.14679
10/31/2023 12,931,781 1,807,693 7.153748
10/13/2023 14,562,237 1,747,512 8.333126
09/29/2023 15,908,106 3,713,026 4.284405
09/15/2023 14,195,024 1,751,157 8.106083
08/31/2023 14,312,120 1,171,990 12.211811
08/15/2023 14,312,217 1,859,658 7.696155
07/31/2023 14,119,789 1,034,688 13.646422
07/14/2023 13,035,551 1,227,302 10.621307
06/30/2023 14,995,756 1,517,575 9.881394
06/15/2023 14,563,273 1,304,531 11.163608
05/31/2023 15,134,557 1,076,380 14.060608
05/15/2023 14,721,123 1,755,503 8.385701
04/28/2023 14,029,192 1,153,616 12.161059
04/14/2023 13,114,306 1,207,158 10.863786
03/31/2023 12,915,981 1,064,039 12.138635
03/15/2023 12,481,294 1,485,009 8.404861
02/28/2023 12,179,645 1,495,557 8.143886
02/15/2023 10,980,509 949,905 11.559586
BACK TO RVNC OVERVIEW
Soma, I totally agree with the $75 coupon! 100% support the coupon! The only catch with the $75 coupons is the practice must order 50 vials to get 50 Coupons! Many practices can not afford to place a $14,750 order which is hurting the small injector. The best way to handle this frustrated small injector is to have the injector offer the patient buy 40 units of Daxi and get 10 free! (1.25 dilution) The RVNC rep provides the free 10 units which are worth $90 versus the coupon at $75.
Evolus reimburses injectors with free products for their coupons! No cash!
Agree, RVNC does not have enough money for a DTC program. RVNC should be all over Instagram, Reels and Tiltok with educational material targeting the patient every day and creating a data base of patients who are asking their providers for Daxi. RVNC should be building Daxi and RHA patient Data Base which will continue to utilize AI elements to cross sell and educate patients!
If Patients start asking their injectors for Daxi, this will drive loyal Botox injectors to bring in the product. To use Daxi is to love Daxi!
Sadly, I bought my RVNC shares before Foley and Foley has made very few correct decisions. Or should we use Foley's words. " I gave too much control to XXXX and did not know what they were doing". If any CEO of a stock traded company managed the company and the stock dropped 80% and their reply was " I did not know what they were doing"....they would be out immediately. Foley might be the magic man for selling companies. As far as running companies, Foley has no idea what he is doing....Foley still thinks the aesthetic injector is the target market.
Have you seen the AbbVie Rinvoq or Skyrizi tv commercials. AbbVie knows the PATIENT IS THE CUSTOMER...just like the NEW Botox TV commercials which i saw last night....and then we have Foley who is advertising to the injectors....Foley has no idea what he is doing or how to sell Daxi.
The Aesthetic Patient is the customer and Foley should be educating the patient on why they should be asking for Daxi....Injectors do not care what product their patients picks...Injectors are there to provide each patient with the product to patient wants AND make money. Foley has lowered the price for Daxi (great move to a bad decision which Foley blamed on the adverting research group...did you catch that today). Foley is to CEO who blames everyone else for every bad decision....Foley does not own any!
Soma, THANK YOU FOR SHARING!!!
Foley continued his false and inaccurate bad path that providers/injectors are or will offer Daxi at the same price as Botox since Daxi has faster onset, better skin tone and longer duration. Hence, patients will chose Daxi at the same price. FOLEY is totally out of touch! EVERY PROVIDER IS OFFERING DAXI AT A PREMIUM TO BOTOX!! THE RVNC SALES REPS ARE INSTRUCTING OFFICES TO CHARGE A PREMIUM!
COULD SOMEONE PLEASE PROVIDE 1 WEBSITE WHERE A PROVIDER IS OFFERING 2 units of Daxi at the same price as 1 unit of Botox.
FOLEY's BAD DECISION MAKING IS KILLING RVNC! WAKE UP INVESTORS!! FOLEY IS A TRAIN WRECK!
ALSO, PRICE IS THE #1 BARRIER TO ENTRY....
SEEMS LIKE FOLEY IS GETTING PAID FROM ALLERGAN TO KILL DAXI SALES...Foley can not be this dumb!!!
Sadly, with Foley’s Leadership and his track record when speaking, RVNC will be in the 4’s this week! Wall Street laughs at Foley who has no idea what he is doing managerially or legally. Will see if Foley says stupid statements on Thursday and creates a new law suit. Foley needs to be removed just like Dustin to save RVNC.
Agree, this injector is not well informed as to the price for Daxi which is now less than Botox This is one of the continuing issues of the botched marketing release and I would also suspect this injector is NOT using a 2 units of Daxi to 1 unit of Botox or 3 units of Dysport. Every vial of Dysport has 300 units which is used 3 units of Dysport to 1 unit of Botox. Dysport absolutely lasts longer than Botox. There is a big injector in my area and they dilute a vial of Botox with 1 cc and dilute a vial of Dysport with 1.2 cc (hyper diluting the Dysport with an extra .2cc) This makes the office more profit and the Dysport life is shorten since there is less active ingredient, This office tells and bills the patients for more Dysport units than they are receiving. . THIS HAPPENS EVERYWHERE!
Doctors/injectors will lie to their patients and tell them they are receiving more active ingredient then they really are! Cosmetic injectors are all about the profit! I saw one doctor in Washington DC who was using half strength product because he was running low on cash and wanted to make more profit.
This hyper hyper diluting of ;Botox, Dysport and Daxi does not happen in Therapeutics since the doctor is paid a flat fee and these therapeutic doctors are not selling the product for cash.
I could give you 6 to 10 aesthetic injectors who hyper dilute their toxin with 4 cc of Bacterial Static (preserved saline) and tell the patient they are getting significantly more active ingredient than they really are.
Yesterday or the day before CNBC interviewed 4 Short Sellers and they discussed factors that they look for in a company which would influence them to short the company stock. If they determine that the company is a "mess", they will short the company. By their definition, RVNC is a mess! Miss allocation of expenses, wrong pricing strategy, poor marketing strategy, instability of the management team, etc. All the corporate elements that a good CEO should be managing which is why RVNC is shorted 20%. Foley lost control and RVNC is unstable.
Dew thinks Foley will right the RVNC ship. I don't think Foley can right the ship because too much instability has occurred on Foley watch. The character of Foley is in question and both RVNC employee and Wall Street do not respect him. Foley needs to be replaced so the RVNC stock can rebound with the support of Wall Street! Foley is also a terrible speaker and needs a Life Coach to help him every time he talks publicly. Foley could be compared to mumbling Joe Biden. :) Leaders need that "gift" of public speaking...Foley does not have the gift!
Yes, RVNC is undervalued due to short selling.
-MHO
Allergan's cosmetic Botox price increase decision is driven by the fact that the corresponding Therapeutic price increase and the revenue/profit gain (driven by the cosmetic price increase) will more than offset the cosmetic market share revenue loss. If no or very little cosmetic market share is lost, Allergan will apply another price increase in July 2024.
Allergan will most likely see a $100 million Therapeutic revenue gain in 2024 at the same Therapeutic sales rate as 2023. Allergan wants to control every injector's patients....they don't want injectors influencing the patient which is why Allergan emails all your patients directly! This has always been Allergan's strategy to take control of each patient via Allergan's communications. This is why Allergan has the in office communications vis hot spots....Allergan wants to control everything including the fact that you the injector continues to make less profit with their products every year!
I know 3 offices who have been loyal Allergan offices for the last 15 years and all 3 are switching their patients to Daxi and RHA which will yield the office at least $500,000 more profit in 2024 at the same volume as 2023....These offices are now growing at 20 to 25% rate, since Daxi is taking patients from other area providers. As Soma noted, 87% of the Botox patients love Daxi and will never go back to Botox...Good Learning! Of the 3 offices I know, 95% patients love Daxi and will not go back to Botox. These offices have also fazed out Juvederm and switched to RHA. Again, RHA is significantly more profitable than Jevederm. And according to my Board Certified Physicians, RHA is a much better dermal filler than Juvderm. The physicians love RHA!
-IMO
Every announced decision/change in the last year has been to correct a bad decision! Foley has not made one positive announcement/decision in the last 12 months. Foley's answer is "He did not know what was going on and allowed too much control to other people". In corporate American, that answer mean Foley was not doing his job as CEO!!! OPUL, pricing strategy, marketing strategy, corporate employee structure, over spending, wrong allocation of expense dollars, the list goes on and on! Hundreds of millions of dollars waisted!
If a president of a Division at AbbVie made just ONE of these bad decisions, he would have been FIRED within 30 days.
The worst is Wall Street has turned their back on FOLEY. The Share price could go to $2 or $3 dollars....Wall Street is laughing at Foley and wants to humiliate him. I am sure Allergan does not want Foley fired because they are loving Foley's terrible decision making! Allergan knows their legal team will definitely be to much for Foley who can not lead anyone or any organization!
Go Seek, i appreciate your thoughts and sadly Wall Street has zero trust in Foley and wants nothing to do with Foley which is why the the shorts and loving life! My guess is Foley has been unfaithful and dishonest with people on Wall Street and they are happy to destroy RVNC. Foley knows who is shorting RVNC!! The only way RVNC will recover is IF FOLEY IS FIRED and new leadership happens. I spoke to serval RVNC staff, and everyone thinks Foley has "lost it" and would love to see him gone.
RVNC needs a solid leader who understands the toxin market and can lead both the company and Wall Street.
Foley's character is destroyed and no one wants him around!
There are many great CEOs who know the toxin market and have created a GREAT company with an average product. Foley has a GREAT product and created a train wreck of a company! He has wrecked every area of the company...product, marketing, culture, trust, expenses, profitability and Wall Street has turned their back on Foley!
Foley has not made ONE positive decision. Not One...Every decision has been a reaction to his bad decision!
Now that Daxi has a “J Code” and RVNC has posted and is hiring a Therapeutic sales team, the sales and shipments of Daxxify should begin on April 1, 2024. Especially to the 200 PREV CD doctors. There are only 1,000 doctors who inject for CD. The top 200 Daxi CD Injectors should cover 80% of the patients! Daxi for CD is the first major advance in treatment in 20 yrs.
The top 20% controls 80% of the market!
I would hope Fumble the Ball Foley puts out a press release 🙄🙄
DAXXIFY™ - HCP230922DBN27
Topic/Issue
Request to establish a new HCPCS Level II code to identify DAXXIFY™.
Applicant's suggested language: JXXXX, “daxibotulinumtoxinA-lanm, for injection 0.1mL”
Summary of Applicant's Submission
Revance Therapeutics submitted a request to establish a new HCPCS Level code to identify
DAXXIFY™ (daxibotulinumtoxinA-lanm). DAXXIFY™ was approved by the Food and
Drug Administration (FDA) under a Biologics License Application (BLA) on September 7,
2022, and a supplemental BLA on August 11, 2023. The original indication for DAXXIFY™
is for adults with glabellar lines, which is an aesthetics indication; and the newer indication is
to treat adults with cervical dystonia (CD). For CD, the recommended dose is 125 units to
250 units given intramuscularly as a divided dose among affected muscles. DAXXIFY™ is a
sterile lyophilized powder supplied in a single-dose vial containing 50 units or 100 units.
CMS Final HCPCS Coding Decision
1. Establish a new HCPCS Level II code J0589, “Injection, daxibotulinumtoxina-lanm, 1
unit”
Effective April 1, 2024
2. Discontinue HCPCS Level II code C9160, “Injection, daxibotulinumtoxina-lanm, 1
unit”
Effective March 31, 2024
Daxi now has $75 patients vouchers for orders of 50 vials or more! Ask your Daxi Rep!
NSM Meeting was last week in Nashville!
Daxi is the best toxin in the WORLD and Foley continues to destroy every aspect of RVNC! Angus Russell is a leader too! There is no way Foley would not have been fired from Shire for the many bad decisions he has made! Russell what are you doing????
Spoke to several sales people who attended the RVNC NSM and they all said the same thing! Nothing new and the tone of the meeting was down because Foley has fired the VP of Sales (RJ)...interesting that 30 plus RVNC employees are all doing the wrong thing and Foley is the only one who is making good decisions. In any other company, Foley would have been fired when RVNC announced the pricing change!
I can not believe CAPITAL WORLD and Valerie Taupin are allowing Foley to continue to destroy RVNC! I have never heard of the CEO staying and firing everyone 24 months after they were hired because the CEO's bad decisions! When Mentor HS had an issue with Silicone Breast implants, the CEO was fired. Had nothing to do with him...but Wall Street had lost faith in him....WALL STREET HATES FOLEY!
I shared Soma's injection info from this message board with a few RVNC reps...their reply was "This is the best info we have received". How sad is that!!!!
The Therapeutic Toxin market is much more profitable than the cosmetic side and Therapeutic is double the size. The only reason Foley has not been fired is the the Therapeutic side. What company would allow the president to fire the entire staff after 24 months and drive the stock price down 80%....Foley is a train wreck and has no idea what he is doing!
From a share holder perspective, which I am, we have to just wait for Therapeutic sales to kick in. Cosmetic sales will now slowly grow simplify do to 2 things: (1) PROFIT OF DAXI (2) DAXI HAS SUPERIOR CHARACTERISTICS TO THE OTHER 3 MONTH TOXINS. Once patients use Daxi, they will not return to Botox.
Over time the Cosmetic patient price for Daxi will erode to a similar price to Botox and Dysport. This injector profit element is not a consideration in the Therapeutic market!
Also, I would not be surprised if RVNC gets bought soon after the Therapeutic release of Daxi. Foley may already have an offer in hand, and this is why Foley has not been fired!
I would not be surprised if Allergan raises the price of Cosmetic Botox another 3.5% in July 2024. Allergan is playing the numbers game and will take the loss in cosmetic market share for the price/revenue gain in Therapeutic Revenue. Allergan did not raise the price of Botox for a few years and they need to catch up!!!
If a cosmetic injector works 48 weeks in 2024, due to the Botox price increase they are getting paid for 46 weeks and the last 2 weeks go to Allergan to pay for the price increase! Allergan just wants your money as Botox is a cash cow which is 20 yrs old....wake up Botox injectors, Daxi is much more profitable and a superior toxin!
As Soma says, 86% of his patients NEVER go back to Botox after Daxi. This is happening to practices all over the USA!
The Jury is still deciding on Fumble the Ball Foley!
My guess is Foley has a few months to clean up the mess HE CREATED OR HE WILL BE OUT like all the employees he fired!
Sadly, WALL STREET HAS PUNTED ON FOLEY.
NO TRUST OR BELIEF IN FOLEY!!
Foley is still restructuring/firing both sales and marketing employees. The quality of the Jeuveau vs Daxi sales rep makes a big difference in the sales success in each area of the country. Daxi sales are booming in certain US states and Jeuveau is doing well in other US states. Jeuveau is basically generic Botox with slightly less active ingredient vs Botox. Jeuveau has become the low price Botox, especially with the recent 3.5% Botox price increase.
Daxi is a completely different peptide toxin with faster onset, improved skin tone and duration variability. The good point is that Daxi is now the most profitable toxin for injectors which will continue to drive market share for patients and injectors. At a 1.25 unit Daxi dilution, the cost is $3.53 per unit and this dilution will provide longer duration than 1 unit of Jeaveau at $4.00. For patients who want the 2 units of Daxi versus 1 unit of Jeaveau, this patient will save money and time. Every injector will make more profit injecting Daxi vs, Jeaveau and significantly more profit than versus Botox. No matter how you cut the pie, Daxi is more profitable for the injector. That is why Soma has switch to Daxi and many other practices are doing the same.
Injectors get paid by their "revenue rate per hour" and not how many times a patient returns to the office. Switching patients to Daxi will generate between $300 to $400 additional PROFIT per hour....over a month for 1 injector, this could be $4,000 to $8,000 more PROFIT! Over 1 year, additional profit of $50,000 to $100,000 versus injecting Jeaveau and making the same profit per patient or injecting Botox and making less profit per patient.
Allergan does not care about Cosmetic Botox and knows that they are losing aesthetic market share. By increasing the price of Cosmetic Botox by 3.5%, this cosmetic price increase will up the price of Therapeutic Botox and increase the therapeutic revenue by over $100 million dollars on an annual basis....
Cosmetic injectors, Allergan does not care about you!
Soma, I feel the marketing message of pricing Daxi equal to Botox is incorrect! Daxi is a Dial a Duration product! If practices use your 1.25 units of Daxi and price it equal to Botox, Daxi provides longer duration than Botox and the injector make more profit via the cost of Daxi is almost $2 less for 1.25 units of Daxi versus 1 unit of Botox!
No other toxin can offer a duration choice!
Then price the 2 units of Daxi to 1 units of Botox at a $2 premium to Botox. So an injector offers 2 Daxi dilutions. 1.25 and 2 …
This way both the injector and the patient win!
Daxi’s Marketing Message should be Dial a Duration! Patient decides how long they want it to last and cost!
Interesting message from Fumble the Ball Foley!
"we want patients to experience the benefits of Daxi without paying a premium"...Foley totally fumbled this one! How long will it take for practices/injectors to provide 2 units of Daxi for the same price as 1 unit of Botox....thoughts??? No Advertising Price Policy...another Foley Fumble!!!!
Wall Street has totally LOST FAITH in Fumble the Ball Foley. He needs to be replaced if for no other reason than this!
I have spoke to several people who Revance has contacted to fill the open VP of Aesthetic Sales...NONE of them want to work for Foley! Foley has a bad reputation in the Aesthetic Industry and on Wall Street!
He must be replaced with someone with good character and who is trusted on Wall Street!
IMHO - Per discussions, Foley fired the current HR Director and hired a new HR Director in the last 30 days. The new HR Director has been firing all the Dustin's management team ( over 30 people). Both the IT and Marketing teams were over staff and are the reason the marketing message, the website, the pricing strategy and all the other messed up areas are a total calamity. Outside companies were solicited and provided guidance and input to correct the internal catastrophe but the internal RVNC people refused to give up control; hence the total disaster and are all fired. The VP of Sales is also being replaced in an effort to create a positive sales culture! Foley was totally out to lunch and is 100% responsible for this setback!
Allergan management is so happy Foley is running RVNC....they think Foley is a Train Wreck!
AbbVie's statement of keeping 68% market share is 100% BS. Both Dysport and Xeomin sales are not public knowledge and Dysport has been taking Botox share for the last few years! Will be interesting to see if Botox sales have increased in Q4 versus Q3 in 2023....the Toxin market is growing at an annual rate of 15% per year. Both Daxi and Jeuveau unit sales increased by 22% over the Q3 2023. My guess is the Botox increase is 4 to 5%....we will see. Botox is losing market share every quarter!!!
Allergan only releases Botox dollar amounts and there is NO price increase until February 1, 2024. Then Botox will get a 3.5% revenue increase...will have to remove the 3.5% to see the true growth of Botox sales in Q1 2024.
If you look at all the company and industry factors:
- RVNC just laid off 30 plus employees to cut admin expense
- Cosmetic Daxi is seeing higher injector adoption with a better understanding of unit mixing, injecting patterns, and profitability as well as counseling patients on expected outcomes. Injectors are now migrating their entire patient base to Daxi and away from Botox.
- Therapeutic Daxi sales will start within the next month or 2
- A Loyalty Program is being rolled out very soon...
- Large MedSpas are now using and beginning to use Daxi as Allergan Continues to increase the price of Cosmetic Botox
What other positive factors?
Allergan announced the price increase early as a way to get practices/injectors to load in product! This is their way of trying to make Q1 2024 quota. Allergan probably loaded in accounts in December 2023 to hit their Q4 number. They now need more loading to make their Q1 2024 number. Q2 2024 revenue will be increased 3.5% just by the price increase for cosmetic and therapeutic to follow.
EAT TO LOSS BOTOX INJECTORS, Ha Ha Ha
The typical injector just lost $10,000 to $20,000 in Botox profit from their bottom line!!! Ha Ha
The 20 yr old car (Botox) now costs each injector an additional $20,000 to drive...no additional benefits!!!!
Ha, I was correct!!! BOTOX PRICE UP!!!!
Allergan is ALL about the PROFIT!!!!
Is Allergan going to support a higher price for the injector....Heck no! EAT THE LOSS INJECTOR!!!
Allergan only cares about their PROFIT....
A vial of Botox now costs $650....OMG How long are you going to drive the expensive old car ( 20 yrs old) when their are now less expense NEW cars which have better ride, interior and more horse power!! LOVE IT!
If and when RVNC raises the price of Daxi by 3 to 4%, I guarantee, Allergan will raise the price of Botox and Galderma will raise the price of Dysport! GUARANTEE!!!
Every PENNY that the Cosmetic Botox price increases is worth about $5 million in Therapeutic Revenue. Allergan can not wait to raise the cosmetic price!!!! I would not be surprised if Allergan raises the price for Cosmetic Botox in 2024 without any other company raising the price of their toxin. AbbVie needs the profit!!!!
The USA Aesthetic Toxin market is experiencing annual growth between 15% to 16% per year. If Daxi simply keeps its aesthetic injectors loyal to Daxi and grows new accounts/ injectors by 10% that is 25% annual aesthetic growth will exceed 30%. Factor in the Annual Therapeutic Market growth at 10% combined with 20% Therapeutic market share growth, and Daxi should exceed 40% plus annual growth very easily!!
This does not include China or Europe . Teaxone will be handling Europe.
That ad is $9 per unit and it takes 2 units of Daxi to equal one unit of Botox. $18 dollars for Daxi versus $14 for Botox and they both cost the injector the same price which is $5.50 for 2 units of Daxi or 1 unit of Botox.
This is exactly why the Daxi adoption rate is low...Daxi costs 25% more for the patient. Pure injector Profit!!!
PRICE is the #1 barrier to entry for a patient!
Allergan/Botox is all over this...telling the practices that Botox is cheaper and that the Daxi patient will not return 3 times a year. The average Botox patient only returns 1.8 times a year, but the Botox reps use 3 times a year. Injectors are so confused...The Daxi Marketing Message is a total flop!
I have not seen or heard of any documentation from RVNC to injectors reversing Foley's stance which did not allow injectors to advertise their Daxi price.
If a practice/injector was report to RVNC management, the management would call the RVNC sales rep and make the rep call the practice/injector. The rep would then be required to ask the account to stop advertising. Remember, the rep is trying to build a relationship and now has to be the bad guy. Terrible Foley policy!
I did hear that RVNC Management is not enforcing this policy any more and if a practice/injector is reported to RVNC Management, the RVNC Management team is NOT contacting the rep and is doing nothing.
https://modernaesthetics.com/videos/looking-ahead-what-to-expect-from-revance-in-2024-and-beyond?c4src=news:sidebar
Looking Ahead: What to Expect from Revance in 2024 and Beyond
In Part 2 of this exclusive interview, Mark J. Foley, Chief Executive Officer at Revance, shares where the company is heading in 2024 and beyond.
Well, now Foley says Revance will have a Loyalty Program in 2024. Allergan is laughing at Foley!!
If you recall, Daxi reps told injectors to charge, $9 per unit per Foley or $18 dollars for 2 units when Daxi was released. Now Foley is telling the injectors, to charge the same as Botox which is 6 to 7 dollars per unit. Foley needs to be removed from RVNC! Foley has no idea how to manage the pricing train wreck he as created!
Foley is not truthful. I don't know of any injectors charging patients the same price for Daxi as Botox. Even the doctors and injectors on this message board, charge a premium price for Daxi versus Botox, even though injectors' pay the same cost for Daxi as Botox. Hopefully, Foley has realized his policy of not allowing injectors to advertise price, was one of his many bad decisions! Doctors and injectors will continue to maximize their profit and price Daxi as a premium product! Injectors will always make their profits and Daxi will not be priced equal to Botox until new injectors who want to grow their patient base, offer Daxi at the same price as Botox and force older more established injectors to compete with lower prices for Daxi.
I believe Allergan had offered $200 million in cash for OPUL, and OPUL elected to take the RVNC 8.5 million shares now worth $50 million.
Maybe Foley will sell to Allergan for 1.2 million shares of Abbive. The AbbVie shares could be the most valuable asset for RVNC! 🤣. Let’s see if Foley continues his streak of bad decisions.
J-codes are permanent reimbursement codes that can be used across all government and third-party insurers nationwide. They are used by government payers and commercial insurers to bill Medicare Part B treatments.
Some benefits of J-codes include:
Standardized code: Allows providers to use the same code across all payers for reimbursement
Reduced risk of billing errors: Helps reduce the risk of billing errors
Pass-through payments: Allows companies to receive pass-through payments through government-sponsored healthcare plans
Streamlined processes: Simplifies and streamlines the billing and reimbursement processes, allowing for efficient claims processing
08 Nov 2023Revance Therapeutics expects approval of daxibotulinumtoxin A in China for the treatment of Glabellar lines in 2024
08 Nov 2023Revance Therapeutics expects approval of daxibotulinumtoxin A in China for the treatment of Torticollis in 2024
08 Nov 2023Revance Therapeutics intends to receive a permanent J-Code for daxibotulinumtoxin A for the treatment of Torticollis in early 2024
Are your assumptions that Fosun Pharma (China) and Teaxone (Europe) will not receive approval to sell Daxi and there will be zero sales of Daxi outside of the USA?
Dew, as the SP continues to drop.20 to .25 per day, how long will the big investor groups ( like Capital World) tolerate Foley?
There has been ZERO good news from RVNC since the CD approval months ago! RVNC has a full staff, yet nothing is happening? Very confusing!!!
What are your thoughts?